Modern conception of carcinogenesis creates opportunities to advance cancer risk assessment

Parsons, 2010, Oncomutations as biomarkers of cancer risk, Environ Mol Mutagen, 51, 836, 10.1002/em.20600 Sweetser, 2017, Utility of the multitarget stool DNA test for detection of colorectal neoplasia, Colorectal Cancer, 6, 83, 10.2217/crc-2017-0010 Berger, 2018, The emerging clinical relevance of genomics in cancer medicine, Nat Rev Clin Oncol, 15, 353, 10.1038/s41571-018-0002-6 Diaz, 2012, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, 486, 537, 10.1038/nature11219 Schmitt, 2015, The influence of subclonal resistance mutations on targeted cancer therapy, Nat Rev Clin Oncol, 13, 335, 10.1038/nrclinonc.2015.175 Parsons, 2018, Multiclonal tumor origin: evidence and implications, Mutat Res Rev Mutat Res, 777, 1, 10.1016/j.mrrev.2018.05.001 Tabassum, 2015, Tumorigenesis: it takes a village, Nat Rev Canc, 15, 473, 10.1038/nrc3971 Soto, 2011, The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory, Bioessays news rev mol, cell dev biol, 33, 332, 10.1002/bies.201100025 Soto, 2011, The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory, Bioessays, 33, 332, 10.1002/bies.201100025 Parsons, 2017, Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas, Environ Mol Mutagen, 58, 466, 10.1002/em.22110 Parsons, 2010, ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue, Cancer Invest, 28, 364, 10.1080/07357901003630975 Myers, 2015, Low-frequency KRAS mutations are prevalent in lung adenocarcinomas, Pers Med, 12, 83, 10.2217/pme.14.69 Myers, 2016, Breast cancer heterogeneity examined by high-sensitivity quantification of PIK3CA, KRAS, HRAS, and BRAF mutations in normal breast and ductal carcinomas, Neoplasia, 18, 253, 10.1016/j.neo.2016.03.002 Myers, 2014, A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid, Mol Carcinog, 53, 159, 10.1002/mc.21953 Brash, 2016, How do mutant clones expand in normal tissue?, 61 Friedrich, 2011, Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009), Regul Toxicol Pharmacol, 60, 225, 10.1016/j.yrtph.2011.04.001 Jacobs, 2015, Regulatory forum opinion Piece∗ transgenic/alternative carcinogenicity assays: a retrospective review of studies submitted to CDER/FDA 1997-2014, Toxicol Pathol, 43, 605, 10.1177/0192623314566241 Nambiar, 2013, The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals, Toxicol Pathol, 41, 1058, 10.1177/0192623313477257 U.S. Food and Drug Administration H, 2005, FDA's guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers Tomasetti, 2015, Variation in cancer risk among tissues can be explained by the number of stem cell divisions, Science, 347, 78, 10.1126/science.1260825 Wu, 2016, Substantial contribution of extrinsic risk factors to cancer development, Nature, 529, 43, 10.1038/nature16166 Nicholson, 2018, Fixation and spread of somatic clones in adult human colonic epithelium, Cell Stem Cell, 22, 909, 10.1016/j.stem.2018.04.020 Curtius, 2017, An evolutionary perspective on field cancerization, Nat Rev Canc, 18, 19, 10.1038/nrc.2017.102 The Cancer Genome Atlas Research, 2014, Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385 Salk, 2018, Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations, Nat Rev Genet, 19, 269, 10.1038/nrg.2017.117 Parsons, 2005, Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development, Mol Carcinog, 42, 193, 10.1002/mc.20083 McKinzie, 2006, ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue® rats treated with N-hydroxy-2-acetylaminofluorene, Mutagenesis, 21, 391, 10.1093/mutage/gel041 Verkler, 2008, Simulated solar light-induced p53 mutagenesis in SKH-1 mouse skin: a dose-response assessment, Mol Carcinog, 47, 599, 10.1002/mc.20415 Meng, 2010, K-Ras mutant fraction in A/J mouse lung increases as a function of benzo[a]pyrene dose, Environ Mol Mutagen, 51, 146 McKinzie, 2011, Accumulation of K-Ras codon 12 mutations in the F344 rat distal colon following azoxymethane exposure, Environ Mol Mutagen, 52, 409, 10.1002/em.20644 Wang, 2011, Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction, Mutagenesis, 26, 619, 10.1093/mutage/ger023 Wang, 2012, ACB-PCR measurement of H-ras codon 61 CAA->CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues, Environ Mol Mutagen, 53, 495, 10.1002/em.21710 Parsons, 2013, Temporal changes in K-ras mutant fraction in lung tissue of Big Blue B6C3F1 mice exposed to ethylene oxide, Toxicol Sci, 136, 26, 10.1093/toxsci/kft190 Goldsworthy, 2002, Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice, Toxicol Pathol, 30, 97, 10.1080/01926230252824770 NTP, 2010, NTP technical report [TR 533] on the photococarcinogenesis of aloe vera [CAS NO. 481-72-1 (Aloe-emodin)] NTP, 2012, NTP Technical Report [TR 568] on the photococarcinogenesis study of retinoic acid and retinyl palmitate [CAS Nos. 302-79-4 (All-trans-retinoic acid) and 79-81-2 (All-trans-retinyl palmitate)] NTP, 1988, Toxicology and carcinogenesis studies of ethylene oxide in B6C3F1 mice